Neurogene (NGNE) News Today → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free NGNE Stock Alerts $32.50 -0.71 (-2.14%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineWilliam Blair Analysts Boost Earnings Estimates for Neurogene Inc. (NASDAQ:NGNE)americanbankingnews.com - May 11 at 1:54 AMNGNE Stock Earnings: Neurogene Beats EPS for Q1 2024investorplace.com - May 10 at 3:26 PMNeurogene Inc. Q1 Loss Beats Estimatesmarkets.businessinsider.com - May 10 at 12:33 PMNeurogene: Q1 Earnings Snapshotwashingtonpost.com - May 10 at 12:33 PMNeurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updatesbusinesswire.com - May 10 at 7:30 AMBrokers Issue Forecasts for Neurogene Inc.'s Q2 2024 Earnings (NASDAQ:NGNE)marketbeat.com - May 10 at 7:06 AMNeurogene Inc. (NASDAQ:NGNE) Expected to Earn Q1 2025 Earnings of ($0.84) Per Shareamericanbankingnews.com - May 10 at 4:02 AMBrokers Set Expectations for Neurogene Inc.'s Q1 2025 Earnings (NASDAQ:NGNE)marketbeat.com - May 9 at 7:54 AMNeurogene (NASDAQ:NGNE) Stock Rating Reaffirmed by HC Wainwrightamericanbankingnews.com - May 7 at 6:22 AMNeurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meetingbusinesswire.com - May 7 at 6:19 AMOptimistic Buy Rating for Neurogene’s NGN-401 Anticipating RMAT Designation and Promising Clinical Datamarkets.businessinsider.com - May 4 at 4:48 PMNeurogene Inc. (NASDAQ:NGNE) Receives $48.25 Consensus PT from Brokeragesamericanbankingnews.com - May 4 at 1:22 AMHC Wainwright Reaffirms "Buy" Rating for Neurogene (NASDAQ:NGNE)marketbeat.com - May 3 at 9:42 PMNeurogene Inc. Forecasted to Earn Q2 2024 Earnings of ($1.19) Per Share (NASDAQ:NGNE)americanbankingnews.com - May 3 at 4:30 AMLeerink Partnrs Comments on Neurogene Inc.'s Q2 2024 Earnings (NASDAQ:NGNE)marketbeat.com - May 2 at 7:49 AMNeurogene (NASDAQ:NGNE) Earns Outperform Rating from Leerink Partnrsamericanbankingnews.com - May 2 at 3:08 AMNeurogene Inc. (NASDAQ:NGNE) Expected to Post Q1 2024 Earnings of ($1.19) Per Shareamericanbankingnews.com - May 2 at 1:24 AMNeurogene Inc. (NASDAQ:NGNE) Receives Consensus Recommendation of "Buy" from Analystsmarketbeat.com - May 1 at 8:52 AMBrokers Set Expectations for Neurogene Inc.'s Q1 2024 Earnings (NASDAQ:NGNE)marketbeat.com - May 1 at 7:51 AMNeurogene (NASDAQ:NGNE) Stock Rating Reaffirmed by Leerink Partnrsmarketbeat.com - May 1 at 7:42 AMLeerink Partners Initiates Coverage of Neurogene (NGNE) with Outperform Recommendationnasdaq.com - April 30 at 6:35 AMBuy Rating Affirmed for Neurogene’s Promising Rett Syndrome Gene Therapy, NGN-401markets.businessinsider.com - April 29 at 7:00 PMNeurogene (NASDAQ:NGNE) Now Covered by Analysts at SVB Leerinkmarketbeat.com - April 29 at 8:22 AMNeurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meetingbusinesswire.com - April 22 at 4:36 PMWilliam Blair Weighs in on Neurogene Inc.'s Q1 2024 Earnings (NASDAQ:NGNE)marketbeat.com - April 19 at 8:17 AMNeurogene (NASDAQ:NGNE) Stock Price Up 3.3%marketbeat.com - April 12 at 2:51 PMNeurogene (NASDAQ:NGNE) Sees Unusually-High Trading Volumemarketbeat.com - April 1 at 4:49 PMNeurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergersseekingalpha.com - March 26 at 2:13 PMNeurogene (NASDAQ:NGNE) Trading Up 5.2%marketbeat.com - March 25 at 4:23 PMWilliam Blair Initiates Coverage on Neurogene (NASDAQ:NGNE)marketbeat.com - March 21 at 8:21 AMNeurogene Inc. (NASDAQ:NGNE) Expected to Post Q1 2024 Earnings of ($0.79) Per Sharemarketbeat.com - March 21 at 8:02 AMNeurogene Inc. Expected to Earn FY2025 Earnings of ($4.15) Per Share (NASDAQ:NGNE)marketbeat.com - March 20 at 6:55 AMNeurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023finance.yahoo.com - March 20 at 6:30 AMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Fusion Pharmaceuticals (FUSN), Caribou Biosciences (CRBU) and Neurogene (NGNE)markets.businessinsider.com - March 19 at 5:08 PMWith 32% ownership, Neurogene Inc. (NASDAQ:NGNE) has piqued the interest of institutional investorsfinance.yahoo.com - March 19 at 9:56 AMNeurogene (NASDAQ:NGNE) Given New $55.00 Price Target at HC Wainwrightmarketbeat.com - March 19 at 8:34 AMNeurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updatesbusinesswire.com - March 18 at 4:14 PMAkero Therapeutics, Inc.edition.cnn.com - March 5 at 10:46 AMNeurogene's (NGNE) Buy Rating Reiterated at HC Wainwrightmarketbeat.com - March 5 at 8:18 AMNeurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trialfinance.yahoo.com - March 4 at 8:38 AMNeurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officerfinance.yahoo.com - March 1 at 6:44 PMNeurogene to Participate in Upcoming Investor Conferencesfinance.yahoo.com - March 1 at 6:44 PMmarketbeat.com - December 19 at 6:01 AM Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem. Protect your retirement savings from the inevitable devaluation of the dollar… NGNE Media Mentions By Week NGNE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NGNE News Sentiment▼0.830.58▲Average Medical News Sentiment NGNE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NGNE Articles This Week▼182▲NGNE Articles Average Week Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ANL News TBPH News FULC News KRRO News PEPG News LXRX News TVTX News TRDA News BMEA News ANNX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NGNE) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsGold Set to EXPLODE!Gold Safe Exchange[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
